Stoke Therapeutics (STOK) Income from Continuing Operations (2018 - 2026)
Stoke Therapeutics' quarterly Income from Continuing Operations came in at 50003000.0 in Q1 2026, down 144.3% year-on-year from 112879000.0 in Q1 2025, and up 13.53% quarter-over-quarter from 57824000.0 in Q4 2025.
Stoke Therapeutics has reported Income from Continuing Operations for 9 years, with the latest figure at 50003000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 144.3% year-over-year to 50003000.0; the trailing twelve-month figure through Mar 2026 stood at 169657000.0 (down 438.83% YoY), and the FY2025 full-year result was 6834000.0, up 92.3% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 50003000.0, up from 57824000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 112879000.0 in Q1 2025, with the low at 57824000.0 in Q4 2025.
- Average Income from Continuing Operations over 5 years is 20709352.94, with a median of 25697000.0 recorded in 2022.
- Peak annual rise in Income from Continuing Operations reached 527.99% in 2025, while the deepest fall reached 441.27% in 2025.
- Tracing STOK's Income from Continuing Operations over 5 years: stood at 25697000.0 in 2022, then declined by 5.07% to 26999000.0 in 2023, then soared by 60.43% to 10683000.0 in 2024, then plunged by 441.27% to 57824000.0 in 2025, then gained by 13.53% to 50003000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 50003000.0 (Q1 2026), 57824000.0 (Q4 2025), and 38347000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -50.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -57.82 Mn |
| Sep 30, 2025 | -38.35 Mn |
| Jun 30, 2025 | -23.48 Mn |
| Mar 31, 2025 | 112.88 Mn |
| Dec 31, 2024 | -10.68 Mn |
| Sep 30, 2024 | -26.43 Mn |
| Jun 30, 2024 | -25.70 Mn |
| Mar 31, 2024 | -26.37 Mn |
| Dec 31, 2023 | -27.00 Mn |
| Sep 30, 2023 | -24.58 Mn |
| Jun 30, 2023 | -30.70 Mn |
| Mar 31, 2023 | -22.59 Mn |
| Dec 31, 2022 | -25.70 Mn |
| Sep 30, 2022 | -26.15 Mn |
| Jun 30, 2022 | -24.69 Mn |
| Mar 31, 2022 | -24.69 Mn |
| Dec 31, 2021 | -24.49 Mn |
| Sep 30, 2021 | -22.64 Mn |
| Jun 30, 2021 | -22.00 Mn |
| Mar 31, 2021 | -16.82 Mn |
| Dec 31, 2020 | -14.59 Mn |
| Sep 30, 2020 | -13.71 Mn |
| Jun 30, 2020 | -12.97 Mn |
| Mar 31, 2020 | -11.06 Mn |
| Dec 31, 2019 | -10.17 Mn |
| Sep 30, 2019 | -8.61 Mn |
| Jun 30, 2019 | -7.82 Mn |
| Mar 31, 2019 | -5.74 Mn |
| Dec 31, 2018 | -4.54 Mn |
| Sep 30, 2018 | -3.32 Mn |
| Jun 30, 2018 | -3.01 Mn |